Department of Psychology, University of Missouri - Kansas City, Kansas City, Missouri (UMKC KCMO).
Department of Psychiatry, University of Missouri - Kansas City, Kansas City, Missouri (UMKC KCMO).
Mo Med. 2021 May-Jun;118(3):239-245.
Polypharmacy, or the daily use of five or more medications, is well documented in older adults and linked to negative outcomes such as medication errors, adverse drug reactions, and increased healthcare utilization. Like older adults, people with multiple sclerosis (PwMS) are susceptible to polypharmacy, owing to the variety of treatments used to address individual multiple sclerosis (MS) symptoms and other comorbidities. Between 15-65% of PwMS meet criteria for polypharmacy; in this population, polypharmacy is associated with increased reports of fatigue, subjective cognitive impairment, and reduced quality of life. Despite evidence of adverse outcomes, polypharmacy among PwMS remains a neglected area of research. This article examines the current literature regarding polypharmacy in MS, as well as implications for clinical practice and directions for future research.
多种药物治疗，即每天使用五种或更多种药物，在老年人中已有充分记录，并与药物错误、药物不良反应和增加医疗保健利用等负面结果相关。与老年人一样，多发性硬化症患者（PwMS）也容易出现多种药物治疗，这是由于为解决个体多发性硬化症（MS）症状和其他合并症而使用了多种治疗方法。在 PwMS 中，有 15-65%符合多种药物治疗的标准；在这一人群中，多种药物治疗与疲劳、主观认知障碍和生活质量下降的报告增加有关。尽管有不良后果的证据，但 PwMS 中的多种药物治疗仍然是一个被忽视的研究领域。本文探讨了 MS 中多种药物治疗的当前文献，以及对临床实践的影响和未来研究的方向。
